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Introduction: Cytomegalovirus-associated thrombosis has been extensively reported in the medical literature,
mainly in immune-compromised patients. However, the association with splenic infarcts has been rarely mentioned.
Case presentation: We report the case of a 38-year-old Caucasian man of Hellenic origin with acute cytomegalovirus
infection presenting with spontaneous splenic infarcts. Echocardiography did not show any vegetations or mural
thrombi. Anticoagulation treatment was not considered due to implication of minor vessels and since cytomegalovirus
was the probable trigger for thrombosis in this patient.
Conclusions: This case report serves as additional evidence for the role of cytomegalovirus in thrombosis.
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Acute infection with cytomegalovirus (CMV) is usually
asymptomatic or may present as an infectious mononucle-
osis like-syndrome. In the immune-compromised patient,
however, the clinical setting of the disease can be expressed
with various life-threatening conditions. CMV-associated
thrombosis has been extensively reported in the medical lit-
erature, mainly in immune-compromised patients. How-
ever, the association with splenic infarcts has been rarely
mentioned [1,2]. While most reports of CMV-associated
thrombosis are referring to immune-compromised trans-
plant recipients or human immunodeficiency virus (HIV)-
positive patients, we report a case of acute CMV infection
in an immune-competent patient, presenting with spontan-
eous spleen infarcts.
Case presentation
A previously healthy, 38-year-old Caucasian obese (body
mass index (BMI) 32) man of Hellenic origin, presented
with a three-week history of hyperpigmented urine, a two
week history of malaise and weakness and a 10-day history
of high-grade fever associated with a nonproductive cough* Correspondence: marianikolettapr@hotmail.com
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distribution, and reproduction in any mediumand no obvious weight loss. During this period, he had
been documenting daily temperatures of 37°C to 39°C. On
admission, our patient was not receiving any medication
and his medical history was irrelevant. He had not been in
recent contact with animals or ill people, was only a social
drinker and not a regular user of tobacco products or
drugs. As a professional driver, he had travelled regularly
in the preceding months.
A physical examination on admission showed an axillary
temperature of 38°C, a pulse rate of 110 beats per minute
(bpm) and a normal blood pressure. Cardiac auscultation
revealed regular S1, S2 clearly perceived with no associ-
ated murmurs. Lung auscultation was unremarkable and
an abdominal examination revealed hepatomegaly and
splenomegaly palpable to an extension of 3cm beneath his
left rib cage. There was no lymphadenopathy or signs of
meningismus. There had been apparent lower limb edema
and no associated tonsillar findings.
His laboratory test results demonstrated a white blood
cell count of 13,660/μL with 63.8 percent lymphocytes.
Activated lymphocytes were observed on blood smear.
Alanine transaminase and aspartate transaminase levels
were mildly elevated (119 and 67U/L, respectively), while
gamma-glutamyltranspeptidase (γGT), alkaline phosphat-
ase (ALP) and lactate dehydrogenase (LDH) were also
high.tral Ltd. This is an Open Access article distributed under the terms of the
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discharge and at one month follow-up are described in
Table 1.
An abdominal ultrasound scan revealed hepatospleno-
megaly with a raised suspicion for a splenic infarct. A
computed tomographic angiogram (CTA) was per-
formed and confirmed the presence of the infarct as well
as the hepatosplenomegaly without any other occlusive
findings. Neither splenic artery nor vein thrombosis was
identified (see Figure 1).
His blood and urine cultures were sterile and trans-
esophageal echocardiography did not show any vegeta-
tions or mural alterations. His serologic test results for
Epstein-Barr virus (EBV), hepatitis B, hepatitis C and HIV
were negative, while his serologic test results for CMV im-
munoglobulin M (IgM) antibodies were positive. A posi-
tive CMV phosphoprotein 65 (PP65) antigenemia assay
confirmed the diagnosis of acute CMV infection, but a
prior hypercoagulable state was still considered. Pro-
thrombin time (PT) value (15.5 seconds reference time
13), international normalized ratio (INR) value (1.25 refer-
ence approximately 1), activated partial thromboplastin
time (aPTT) value (43.6 seconds range 24 to 36) and D-
dimers (DD) levels (5.20μg/ml range 0 to 0.5) were
elevated, fibrinogen (391mg/dl range 200 to 400) and
homocysteine (8.47μmol/L range for men 30 to 59 years
6.3 to 11.2) were within normal range. His antiphospholi-
pid antibodies (APA) panel and anticardiolipin antibodies
(ACA) were negative. Finally, the rest of the exams were
as follows: antithrombin 88 percent (range 80 to 120), pro-
tein C 74 percent (range 70 to 130) and protein S 52 per-
cent (range 65 to 140). Factor V-Q506 (Leiden) and FII
(G20210A) were negative.
At this point, anticoagulation treatment was considered,
but it was ruled out since CMV was the probable trigger or
cause of the thrombosis in our patient and as the majorly
implicated vessels were minor ones. Ganciclovir treatment
was also considered but not administrated since it is an
agent primarily indicated for immune-compromised and
occasionally in immune-competent patients with target-
organ involvement.
An abdominal ultrasound scan four days after admission
revealed no significant changes and our patient was subse-
quently discharged from hospital two days after without
being given any medication, with the diagnosis of CMV
infection with associated splenic infarct. Our patient was
advised to follow a regular check on an outpatient basis in
a months’ time with ultrasound control and monitoring of
the relevant blood parameters. He was also encouraged to
undergo a control blood sampling one month after and
the examination revealed a substantial increase in protein
S levels and a normalization of all other biochemical pa-
rameters. The ultrasound check performed the same day
confirmed that the splenic echogenicity return to normal.Discussion
We report the case of an immune-competent man with
concomitant acute CMV infection and thrombosis, an
association reported previously in the medical literature
mainly in immune-compromised patients. The exact
pathologic mechanism by which CMV triggers throm-
bosis is still unclear. Current theories suggest that CMV
induces thrombosis by promoting platelet and leukocyte
adhesion to infected endothelial cells, or, alternatively,
by increasing the circulatory levels of factor VIII. Other
theories suggest that CMV induces transient APA pro-
duction and enhances vascular smooth-muscle prolifera-
tion. Genetic predisposing factors for thrombosis in
patients with CMV-associated thrombosis, such as factor
V Leiden mutation, were also previously reported [3].
CMV infection is also known to lead to elevation of both
platelet-derived growth factor and transforming growth
factor-β. These growth factors can cause vascular cell
wall proliferation [4]. It has been shown that CMV infec-
tion can also cause vascular cell activation and expres-
sion of adhesion proteins leading to increased platelet
and leukocyte adhesion. This proinflammatory effect can
cause changes that alter the anticoagulant environment
of the vascular endothelium so that it favors coagulation
[5]. CMV has also been shown to increase the levels of
interleukin (IL)-1β, IL-6, tumor necrosis factor (TNF)-α,
and other cytokines that have inflammatory properties
[6,7]. Finally, few cases of immunologic alterations, such
as cryoglobulinemia have been described in the acute
phase of primary CMV infection in immune-competent
patients [8]. Therefore, CMV infection, as a result of ei-
ther one or a combination of these mechanisms, can in-
duce vascular changes that may trigger a cascade of
events that lead to inflammation and thrombosis [9]. Re-
gardless of what the causative mechanism is, there is
growing evidence that CMV infection may induce vascu-
lar damage with associated thrombosis that may be life-
threatening.
Our initial hypothesis has been that of a suppressive
impact of CMV upon the mechanism of action of pro-
tein S (PS) rather than that of an eventual mechanical
endothelial damage. As is well known, PS is a vitamin K-
dependent anticoagulant protein. It mainly functions as
a cofactor to facilitate the action of activated protein C
(APC) on its substrates, activated factor V (FVa) and ac-
tivated factor VIII (FVIIIa). To support the significance
of a low PS level we should co-evaluate the existence of
a laboratory proof of activated protein C resistance
(APCR). APCR is the inability of protein C to cleave FVa
and/or FVIIIa, which allows for longer generation of
thrombin and may lead to a hypercoagulable state. Pro-
tein S deficiency, on the other hand, may be hereditary
or acquired, the latter being usually due to hepatic dis-
eases, nephrotic syndrome, a vitamin K deficiency or
Table 1 Laboratory data pre-/post-admission
Laboratory results on admission
General
Admission Discharge 1 Month later
WBC 13660/μl (range 4000-11000/μl) 8780 7700
NEUT 19.2% (range 50-70%) 33.6 42.4
LYMPH 63.8% (20-40%) 56.3 48.1
MONO 11.6% (range 0-8%) 8.9 8.2
Hct 38% (range 36–52%) 37.6 40.3
Hgb 13.3gr/dl (11.8-17gr/dl) 12.6 13.3
PLTs 176,000/μl (range 150,000-400,000/μl) 279,000 330,000
MCV 85fl (range 79-98fl) 87,2 86,5
ESR 20 (range 0–10) 10 8
CRP 6.7U/L (range <0.5U/L) 3 1.36
Microscopic appearance
Activated lymphocytes Many
Coagulation profile – thrombophilia screening
Admission Discharge 1 Month Later
PT 13.8sec (ref 13) 14 13,6
aPTT 35.6sec (ref 24–36) 37.7 34.2
INR 1.08 (ref 1) 1.10 1.06
D-dimers 3,93μg/ml (ref 0–0,5) 5.13 2.24
Fibrinogen 338mg/ml (ref 200–400) 369 479




Anti-thrombin III 88% range 80-120
Protein S 52% (normal values 65–140) 71%
APC-R 153sec (normal >120)
Protein C 74% (normal range 70–130) 75%
FV-Q506 (Leiden) Not detectable
FII (G20210A) Not detectable
MTHFR (C677T) Heterozygote
Anti-β2-glycoprotein I (β2GPI-I) Negative
FV (H1299R) Not detectable
MTHFR (A1298C) Not detectable
Serologic tests
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Table 1 Laboratory data pre-/post-admission (Continued)
C3 158mg% (range 79.0-152.0)
C4 21.3mg% (range 16.0-38.0)
PNH Negative
Biochemical profile
Admission Discharge 1 Month Later
Ca 8,6 mg/dl (range 8,8-10,4) 9,1 9,5
Mg 2,2 mg/dl (range 1,6-2,3) 2 2,2
Glu 110 mg/dl (range 75-115) 86 91
Urea 26 mg/dl (range 15-54) 27 30
Crea 1 mg/dl (range 0,9-1,6) 1 1
Ur acid 4,1 mg/dl 4 4
TP 6,3 mg/dl (range 6-8,4) 6,5 6,4
Alb 3,3 mg/dl (range 3,5-5,5) 3,2 3,4
Glob 3 mg/dl (range 2,5-3,4) 3,3 3
Bil tot 1,07 mg/dl (range 0,1-1,3) 0,96 1,14
SGOT 67 U/L (range 5-40) 41 28
SGPT 119 U/L (range 5-40) 93 57
γGT 294 U/L (range 10-50) 296 200
LDH 382 U/L (range 120-230) 339 219
CPK 64 U/L (range < 190) 47 59
ALP 182 U/L (range 34-104) 175 139
WBC, white blood cells; Neut, neutrophils; Lymph, lymphocytes; Mono, monocytes; Hct, hematocrit; Hgb, hemoglobin; PLTs, platelets; MCV, mean cell volume; ESR,
erythrocyte sedimentation rate; CRP, C-reactive protein; INR, international normalized ratio; aPTT, activated partial thromboplastin time; PT, prothrombin time; DD,
D-dimers; APA, antiphospholipid antibodies; ACA, anticardiolipin antibodies; LA, lupus anticoagulant; APCR, activated protein C resistance; FV, factor V; FII, factor II;
MTHFR, methylene-tetra-hydro-folate reductase; AFV, activated factor V; AFVIII, activated factor VIII; ALP, alkaline phosphatase; BMI, body mass index; CMV,
cytomegalovirus; DVT, deep venous thromboembolism; EBV, Epstein-Barr virus; HBV, hepatitis b virus; HCV, hepatitis c virus; HIV, human immunodeficiency virus;
ANA, anti-nuclear antibodies; ANCA, anti-neutrophilic cytoplasmic antibodies; C3, complement 3; C4, complement 4; PNH, paroxysmal nocturnal haemoblobinuria;
PP65, phosphoprotein 65; Ca, calcium; Mg, magnesium; Glu, glucose; Crea, creatinine; Ur, uric acid; Tp, total proteins; Alb, albumin; Glob, globulins; Bil tot, total
bilirubin; SGOT, serum glutamic oxaloacetic transaminase; SGPT, serum glutamic pyruvic transaminase; γGT, gamma-glutamyltranspeptidase; LDH, lactate
dehydrogenase; CPK, creatinine phospho-kinase; ALP, alkaline phosphatase.
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mune complexes, inducing increased clearance of PS
or interfering with the protein C-protein S system [10].
Protein S deficiency usually manifests clinically as ven-
ous thromboembolism (VTE). The association of PS
deficiency with arterial thrombosis appears less and
weaker. Arterial thrombosis is not evident with other
hereditary anticoagulant abnormalities (for example
PC or antithrombin deficiency, and factor V Leiden
gene mutation). The normalization of PS concomitant
to the cessation of the clinical manifestations of the
CMV infection appears to be substantial to the sustain-
ment of our hypothesis, although protein S is usually
consumed during the acute phase of thrombosis to
counterbalance the prothrombotic factors so the rise
of PS a month after could also be explained by this
phenomenon. Therefore, there is not really strong evi-
dence in favor of PS as major a mechanism of CMV
thrombosis. Other concomitant risk factors inevitably
contribute to thrombosis provocation.Fever accompanied by splenic infarcts in an immune-
competent patient can be seen in endocarditis, in viral
infections such as EBV, in infectious vasculitis as
observed in neisserial infections and in various other
noninfectious conditions, including sickle cell anemia,
autoimmune vasculitis and hypercoagulable states. Ex-
tensive reports on concomitant acute CMV infection
and thrombosis in immune-competent patients exist
[1,2,11,12]. Moreover, reports on acute CMV infection
and splenic infarcts in immune-competent patients are
even more rare. In the immune-competent host with
CMV, vasculitis with thrombosis appears to be ex-
tremely rare. We identified very few cases reported in
the literature [2,13-16]. Two 31-year-old women with
apparently active CMV disease developed hepatic vein
thrombosis but both patients were taking oral contra-
ceptive pills, which predispose patients to thrombosis
[17,18]. A four-month-old girl with acute CMV infec-
tion also developed portal vein thrombosis, but she had
PC and PS deficiency, which very likely contributed to
Figure 1 Splenomegaly associated with abnormal low-density sphenoid-type mass located at the outer left part of the organ.
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with a two-week history of fever, myalgia and cough
showed a transiently elevated anticardiolipin IgG with a
normal anticardiolipin IgG and a negative lupus anti-
coagulant [13]. A meta-analysis showed that deep ven-
ous thromboembolism/pulmonary embolism (DVT/PE),
splanchnic vein thrombosis and splenic infarction were
the most prevalent thromboses associated with acute CMV
infection with splanchnic vein thrombosis being the one
most prevalent among immune-competent patients [2].
Clinical and laboratory observations in nine other cases, in
other studies, demonstrated cytomegalovirus mononucle-
osis to be common among young adults giving credit to the
fact that this diagnosis should be considered in all patients
with detected mononucleosis-like antibodies, including
those with lymphadenopathy and splenomegaly [16].Conclusions
CMV is a rare, but potentially significant, cause or precipi-
tating factor for thrombosis in immune-competent hosts.
We think that all patients with unexplained fever and
spontaneous thrombosis should be screened for CMV in-
fection; in cases of splenic infarcts due to thromboembol-
ism or congenital hypercoagulability, anticoagulation is
mandatory, while in cases of splenic infarcts alone, CMV
infection may influence the decision on whether or not to
start anticoagulation therapy. Many theories on the mech-
anism of interaction between CMV and human organisms
have been postulated, a fact that makes evident the need
for further investigation and clinical observation.This case report serves as additional evidence for the
role of CMV in thrombosis. Cytomegalovirus-associated
vascular thrombosis is a rare but increasingly reported
phenomenon and should be considered in the differen-
tial diagnosis of splenic infarction once more common
diagnoses, such as endocarditis and lymphoma, have
been excluded.Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for re-
view by the Editor-in-Chief of this journal.
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